A mini-panel of semi-synthetic analogs of the Amaryllidaceae alkaloid lycorine was screened for cytochrome P450 3A4 (CYP3A4) inhibitory activity, the most potent of which exhibited inhibition as low as 0.21 μM. Elements of this novel pharmacophore unravelled include bulky lipophilic substitution at C2 in conjunction with a small hydrogen bond donor/acceptor at C1, or bulky electron-rich substitution at C1 in conjunction with a vicinal hydrogen bond donor/acceptor.
The plant family Amaryllidaceae is endowed with a compendium of structurally diverse alkaloids biogenetically derived from the common amino acidderived precursor norbelladine 1 (Scheme 1) [1, 2] . Crinine 2, galanthamine 18 and lycorine 22 are representative of the three major structural types within the family although six other minor groups are known to occur, exemplified by homolycorine 29, tazettine 30 and montanine 31 [2] . The Amaryllidaceae has occupied a central role in chemical-biology, providing diverse structural architectures that have proven inspirational in total synthesis and methodological investigations, and importantly in the discovery of leads with diverse biological activities [1] [2] [3] . Chief amongst these is the reversible acetylcholinesterase (AChE) inhibitor galanthamine 18, now approved as a prescription drug in the treatment of Alzheimer's disease [4] . Alkaloids of the crinane series are known for a host of diverse biological functions including antimalarial, anticancer, protein synthesis inhibition and antiproliferative action [5] . Work by us in this area uncovered the potent apoptosis-inducing ability of the α-ethano bridged crinane alkaloids crinamine 10 and its C3 epimer haemanthamine 14, which were shown to be selectively more active than β-variants [6] . Biologically, the lycorine series is perhaps the most widely examined within the Amaryllidaceae. Lycorine 22 exhibits a wide range of biological activities including antiviral, antifungal and antiprotozoal effects [7, 8] . As a potential chemotherapeutic, lycorine has shown promise as an antiproliferative agent in a number of cell lines [7d-f], although less potent than the related lycorane derivatives pancratistatin 27 and narciclasine 28 [9] [10] [11] . We recently documented the potent apoptosis-initiating properties of lycorine 22 and its related A-ring analog pseudolycorine 21 in human leukemia (Jurkat) cells, uncovering valuable structural details of this cytotoxic pharmacophore [8] .
In addition to the study of the antiproliferative effects of Amaryllidaceae constituents, our group has been concerned with the investigation of human cytochrome P450 interactions of certain of these alkaloids based on what appears to be a common P450 interactive pharmacophore. Cytochromes P450 (CYP450) are heme-containing mono-oxygenase enzymes involved in the detoxification of a wide variety of xenobiotics such as drugs and environmental toxins [12] [13] [14] . The CYP3A subfamily comprises about 30% of the total liver cytochrome P450 enzyme pool in humans, and the isoenzyme CYP3A4 accounts for approximately 60% of drugs metabolized [13, 14] . We have been concerned with the elucidation of CYP3A4-drug interactions to provide information of value in the preparation of a selective anticancer agent. We recently documented the human CYP3A4 inhibitory activity of a compound library comprising 26 Amaryllidaceae alkaloids and derivatives (Scheme 1, 2-28) [15] . Of interest, pancratistatin 27 exhibited low interaction with CYP3A4 while narciclasine 28 proved to be a potent inhibitor and the potent AChE inhibitors galanthamine 18 and sanguinine 19 were seen to have no observable effect on CYP3A4 inhibition [15] . We also revealed that lipophilic substitution at positions 1 and 2 in the lycorine series 22 [15] and in seco-pancratistatin analogs [16] resulted in the formation of potent CYP3A4 inhibitors [15] . For example, the C2 TBSlycorine analogs 23 and 24 had Ki values of 0.26 and 0.21 μM respectively, an order of magnitude less active than the clinically used antifungal P450 inhibitor ketoconazole. Hence it is clear that the molecular space around the C1 to C2 region in these compounds strongly interacts with CYP3A4; in particular, lipophilic substitution can result in potent CYP3A4 interactions. The C1 benzoate ester of pancratistatin has been shown to be one of the most potent anticancer derivatives in the lycorane series [17a] , results that have prompted synthetic efforts to access C1 functionalized derivatives [17b]. In the present communication, we report the synthesis of the C-1 benzoate and structural analogs within the lycorine series and document their potent and selective interactions with human CYP3A4.
The reaction of lycorine 22 with TBSCl in pyridine afforded the novel monosilyl ether 23 in 56% isolated yield (81% based on recovery of lycorine). No bis-silylated product was detected during the course of the reaction. Direct chemoselective access to the tertbutyldimethylsilyl ether 23 allowed us to introduce a benzoate group at C1 as in 32, obtained in near quantitative yield from 23 upon reaction with benzoyl bromide and pyridine. The 1 H NMR spectrum (see Experimental section) showed the expected deshielding effect on H1 (δ 5.82, dd, J = 3.5, 1.4 Hz). Desilylation of 32 was straightforward with tetrabutylammonium fluoride (TBAF) in tetrahydrofuran (THF) affording 1-benzoyllycorine 33, the proton spectrum of which indicated a slight upfield shift for H2 (δ 4.35, dd, J = 3.5, 2.1 Hz) compared to 32. Acetylation of 33 utilizing acetic anhydride and pyridine then provided in 98% isolated yield 1-benzoyl-2-acetyllycorine 34 which had the H2 resonance at δ 5.40 (dd, J = 3.5, 2.1 Hz). The mini-library consisting of compounds 22-26, 29-31 and 32-34 was screened for CYP3A4 inhibitory activity via kinetic monitoring of the conversion of 7-benzyloxyquinoline (BQ) to 7-hydroxyquinoline (HQ) by fluorometric measurement of emission at 538 nm after excitation at 410 nm, utilizing ketoconazole as control (Table 1 ) [15, 16] . The IC 50 curves depicted in Figures 1 and 2 show the effect of ketoconazole and compound 33 on the biotransformation of 7benzyloxyquinoline to 7-hydroxyquinoline by CYP3A4.
As mentioned above, we recently showed that compounds 23 and 24 are the most potent inhibitors of CYP3A4 within the lycorine series with Ki values of 0.26 and 0.21 μM, respectively [15] . Removal of the silyl group resulted in a ~30-fold drop in activity as seen for 1-acetyllycorine 25 (Ki 7.6 μM), while activity dropped even further with the introduction of an additional acetate group as seen in compound 26 (Ki 11 μM) [15] . All three C1-benzoate derivatives 32, 33, and 34 are now shown to be potent inhibitors of CYP3A4. Hence, the introduction of the benzoate entity to C1 provides potent CYP interaction with or without inclusion of a lipophilic substituent at C2. The corresponding C1-acetate derivatives showed significantly less potency and required the inclusion of the bulky substituent at C2. We have now demonstrated that derivatives containing large substituents at C1 alone (compound 33) or at C2 alone (compound 23) exhibit submicromolar potency to CYP3A4, while lipophilic substitution at both positions (compounds 24, 32 and 34) results in similar, or only slightly diminished activity. As discussed above, the C1 benzoate analog of pancratistatin is reported to be the most potent anticancer compound in the pancratistatin 27 series [17] . The potency of C1/C2 lipophilic lycorine derivatives is rationalized in terms of an interaction of the top portion of these molecules with a lipophilic binding site in the enzyme [15] . Small, polar groups at C1 (hydroxyl, acetoxy) in conjunction with a lipophilic group at C2 (as in 23 and 24) are important for potent CYP3A4 inhibition as the simple acetate 26 is significantly less active (Ki 11 μM) [15] .
Nonetheless, a bulkier substituent at C1 alone (as in 33) is sufficient to allow significant CYP3A4 interaction. The most significant result is therefore the potency of the otherwise unfunctionalized C1 benzoate 33, in view of the anticancer activity of such derivatives in the pancratistatin series [17] . Other interesting insights [15] , which was not as pronounced in the benzoyl series. In this case there was only a ~4-fold drop in activity in the conversion of 32 (Ki 0.99 μM) to 33 (Ki 0.23 μM). As far as ring-A substitution is concerned, there is no apparent modulation in CYP3A4 activity as both lycorine 22 and pseudolycorine 21 were inactive [15] . The significant CYP3A4 interaction demonstrated by narciclasine 28 [15] is anomalous at present, given the large number of natural [15] and semi-synthetic [16] derivatives investigated. Based on the structural similarity of pancratistatin 27 (non CYP3A4 interactive) and narciclasine 28 it would appear that the C1-C10b olefin is a requirement for this activity [15] , irrespective of lipophilic substitution at C2 in narciclasine. This is not surprising given the role of P450 enzymes in oxidizing olefinic substrates. In contrast, lycorine which contains a C3-C4 bond is inactive. We are currently investigating the role of the double bond in narciclasine in respect to its potent CYP3A4 inhibitory effects.
In conclusion, we have shown that bulky substitution at either C1 or C2 in the lycorine alkaloid series results in potent inhibition of human CYP3A4, while substitution at both positions modulates the activity to a moderate degree only. The CYP3A4 potency of the C1 benzoate of the alkaloid lycorine 33 is most significant, given the anticancer and other activities reported for the parent alkaloid 22 [7a-g] and its relation to those in the pancratistatin series. A comprehensive and consistent view on the role of the C1 and C2 substituents and their interactions with human CYP3A4 enzyme is now available. Given the clinical potential of the lycorine group of compounds as anticancer agents, these observations provide valuable insight into regions of this pharmacophore likely to interact with CYP3A4 of significant consideration in the design, synthesis and biological evaluation of emerging anticancer agents.
Experimental
General: Melting points (uncorrected) were measured on a Gallenkamp melting point apparatus. Optical rotations were determined on a Perkin-Elmer 241 polarimeter. IR spectra were measured on a Bio-Rad FTS-40 series spectrometer in dry film. CIMS were run on a Micromass Quattro Ultima spectrometer fitted with a direct injection probe (DIP) with ionization energy set at 70 eV and HRMS (CI) were performed with a Micromass Q-Tof Ultima spectrometer. 1 H and 13 C NMR spectra were recorded on a Bruker AV700 spectrometer. Silica gel (Merck 70-230 mesh) was used for CC, silica gel SIL G/UV 254 for analyt. and SIL G-25/UV 254 for prep. TLC (both Macherey-Nagel). Spots on chromatograms were detected under UV light (254 nm) and by Dragendorff's reagent stain.
Extraction and isolation of alkaloids: Lycorine 22, homolycorine 29, tazettine 30 and montanine 31 were obtained from authenticated plant sources as previously described [18] , and voucher specimens have been deposited in the Herbaria at the National Museum (Bloemfontein, South Africa) or the Institut Botanic (Barcelona, Spain). All alkaloids were single components by both NMR and TLC analysis.
Cytochrome P450 3A4 inhibition assay: CYP3A4 assays were carried out according to procedures we have recently published [15, 16] .
Synthesis of 2-tert-butyldimethylsilyllycorine 23:
Lycorine 22 (30 mg, 0.105 mmol) was dissolved in 0.315 mL of dry, distilled pyridine to which was added tert-butyldimethylsilyl chloride (24 mg, 0.158 mmol) dissolved in a minimum volume of dichloromethane, and the solution stirred at room temperature for 12 hrs. After this time, residual lycorine (9 mg) was filtered off and the supernatant taken into saturated NH 4 Cl solution (1 mL) and extracted with dichloromethane (5 x 1 mL), the combined organic fractions dried over Na 2 SO 4 and solvent removed under reduced pressure. The crude gum obtained was chromatographed on silica gel to give 23 as an off-white powder (21.4 mg, 56%). MP:130-132ºC. 
Synthesis of 1-benzoyl-2-tert-butyldimethylsilyl lycorine 32:
Silyl ether 23 (30.0 mg, 0.0747 mmol) was dissolved in 0.224 mL dichloromethane to which was added consecutively dry pyridine (0.012 mL, 0.149 mmol) and benzoyl bromide (0.015 mL, 0.112 mmol) and the solution stirred at room temperature for 5 hrs when TLC (30% ethyl acetate/hexane) indicated the reaction to be complete. The mixture was then diluted with saturated NaHCO 3 solution (1 mL) and extracted with dichloromethane (5 x 1 mL), the combined organic fractions dried over anhydrous Na 2 SO 4 and solvent removed under reduced pressure to yield a gum which was purified on silica gel eluting with 30% ethyl acetate/hexane to give compound 32 (36.5 mg, 96%) as a yellow oil. 1H, s, 7.37 (2H, dd, J = 7.7, 7.7 Hz, 7.49 (1H, dd, J = 7.7, 7.7 Hz, 7.87 (2H, d, J = 7.7 Hz, H-2'/H-6'). (8), 295 (10), 250 (15), 237 (18), 179 (30), 167 (12), 122 (22) , 105 (100), 77 (15) .
Synthesis of 1-benzoyllycorine 33:
Silyl acetate 32 (50 mg, 0.0989 mmol) was dissolved in 0.5 mL of dry THF to which was added 1M tetrabutylammonium fluoride (TBAF) solution (0.150 mL, 0.150 mmol) and the solution left stirring at room temperature until TLC (30% ethyl acetate/hexane) indicated the reaction to be complete (~1 hr). The mixture was then diluted with saturated NH 4 Cl solution (1 mL) and extracted with ethyl acetate (5 x 1 mL), the combined organic fractions dried over anhydrous Na 2 SO 4 and solvent removed under reduced pressure to yield a gum which was purified on a silica gel column eluting with (30% ethyl acetate/hexane) to give compound 33 as a light-yellow oil (38.2 mg, 98%). (15) , 376 (10), 306 (12), 279 (9), 250 (30), 227 (8), 190 (9) , 122 (23), 105 (100), 77 (15) .
Synthesis of 1-benzoyl-2-acetyllycorine 34:
Hydroxy acetate 33 (50.0 mg, 0.128 mmol) was dissolved at room temperature in dichloromethane (0.640 mL) to which was added consecutively dry pyridine (0.020 mL, 0.256 mmol) and acetic anhydride (0.018 mL, 0.192 mmol) and the solution stirred for 3 hrs when TLC (30% ethyl acetate/hexane) indicated the reaction to be complete. The mixture was then diluted with saturated NaHCO 3 solution (1 mL) and extracted with dichloromethane (5 x 1 mL), the combined organic fractions dried over anhydrous Na 2 SO 4 and solvent removed under reduced pressure to yield a gum which was purified on silica gel eluting with (30% ethyl acetate/hexane) to give compound 34 (54.3 mg, 98%) as a yellow oil. 
